Correction {#Sec1}
==========

Following publication of the original article \[[@CR1]\], the authors notified us of a misleading data presentation in Table [4](#Tab1){ref-type="table"}. The table's sub header incorrectly presented the information in the first part of the table, BINARY DATA. We have therefore modified this sub header and added a second sub header to the table, corresponding to CONTINUOUS DATA.

The original publication has been corrected. Table [4](#Tab1){ref-type="table"} as initially published is presented below.Table 4Individual trial estimates not combined in meta-analysesFirst author & publication yearOutcomeMeasurement pointInterventionControlEffect estimateSDMmean (SD)Total (N)Usual Caremean (SD)Total (N)SMD (95 % CI)BINARY DATA *Patient-reported ordering of screening*  Krist, 2007 \[43, 44\] (Woolf, 2005)patient-reported PSA tests ordered (patients' exit questionnaires)immediately after consultation1) web-based DA176226no pre-visit educational material and no DA during discussions with physicians60750.97 (0.85 to 1.11)2) paper version of DA in 1)15119660750.96 (0.84 to 1.10) *Actual ordering of screening*  Landrey, 2013 \[42\]PSA tests order by clinicians (chart-documented)following doctor's appointmentflyer85136no flyer861471.07 (0.88 to 1.29)  Krist, 2007 \[43, 44\] (Woolf, 2005)physician-reported PSA tests ordered (chart-documented)immediately after consultation1) web-based DA176205no pre-visit educational material and no DA during discussions with physicians66700.91 (0.84 to 0.99)2) paper version of DA in 1)15518266700.90 (0.83 to 0.98) *Physicians' recommendations: towards screening*  Wilkes, 2013 \[41\]doctor's recommendations towards PSA screening: unannounced standardised patients (physicians' questionnaires)after clinic visit^b^1) MD-Ed + A1636CDC educational brochures on PC34430.56 (0.38 to 0.84)2) MD-Ed244134430.74 (0.55 to 1.00) *Physicians' recommendations: neither nor against screening*  Wilkes, 2013 \[41\]doctors neither suggested nor recommended for or against PSA test: unannounced standardised patients (physicians' questionnaires)after clinic visit^b^1) MD-Ed + A1836CDC educational brochures on PC6433.58 (1.59 to 8.06)2) MD-Ed14416432.45 (1.04 to 5.76) *Patient-estimates of lifetime risks*  Gatellari, 2003 \[45\]how likely men were to give a correct estimate (within 2%) of the lifetime risk of dying from PC (correct answers over incorrect answers)unclear (questionnaires mailed 3 days post-consultations)32-page (3085-word) evidence-based booklet55104968-word pamphlet by the Australian government37513.22 (4.30 to 40.66)how likely men were to give a correct estimate (within 10%) of the lifetime risk of developing PC (correct answers over incorrect answers)59104181083.40 (2.16 to 5.36)CONTINUOUS DATA *Satisfaction with the visit*  Wilkes, 2013 \[41\]patient-reported satisfaction with the visit: planned visits (sum of 5 satisfaction items: 5 = least satisfied, 20 = most satisfied)after clinic visit^b^MD-Ed + A18 (3.00)102CDC educational brochures on PC18 (3.00)2910.00 (-0.23 to 0.23)patient-reported satisfaction with the visit: clinic visits by patients (sum of 5 satisfaction items: 5 = least satisfied, 20 = most satisfied)MD-Ed18 (2.00)18818 (3.00)2910.00 (-0.18 to 0.18) *Men's views towards screening*  Gatellari, 2003 \[45\]men's views weighted towards or against reasons for having PSA testing (Scoring -5 to 5. Positive: weighting for; Higher: stronger weighting for; Negative: weighting against; Lower: stronger weighting against)^b^unclear (questionnaires mailed 3 days post-consultations)32-page (3085-word) evidence-based booklet1.70 (1.58)106968-word pamphlet by the Australian government1.4 (1.59)1080.19 (-0.08 to 0.46) *Decisional conflict*  Gatellari, 2003 \[45\]decisional conflict (9-item factors contributing to uncertainty scale; higher scores = greater decisional conflict)unclear (questionnaires mailed 3 days post-consultations)32-page (3085-word) evidence-based booklet21.60 (4.73)106968-word pamphlet by the Australian government24.3 (4.77)108-0.57 (-0.84 to -0.29)*PC* Prostate Cancer, *SDM* Shared Decision-Making, *MD-Ed + A* Physician Education and patient Activation, *MD-Ed* Physician Education, *DA* Decision Aid, *CDC* Centers for Disease Control and Prevention, *PSA* Prostate Specific Antigen, *n* number of patients with events or number of events, *N* total number of patients per group, *RR* Relative Risk, *SD* Standard Deviation, *SMD* Standard Mean Difference, *CI* Confidence Intervals^a^Questionnaire adapted from an attitudinal measure of the mammography screening instrument^b^Men followed-up in 6-16 weeks depending on the timing of the standardised visit: about 6 weeks after the intake survey for control physicians, 6-10 weeks for MD-Ed physicians, and 6-16 weeks for MD-Ed+A physicians
